It is a phosphodiesterase enzyme inhibitor which increases force of contraction of heart.
| Composition : | 100mg/20ml | | Indications : | CHF | | Contraindications : | Hypersensitivity | | Safety Profile : | Fluid and electrolyte imbalance, cardiomyopathy, aortic diseases, aortic diseases, pregnancy and lactation. | | Adverse Effects : | Cardiac arrhythmias, nausea, hepatotoxicity, hypotension, G.I.Disturbances. | | Drug Interactions: | Enhanced hypotensive response when used with disopyramide. | | Dosage: | Loading dose 0.75 mg/kg/i.v. | | Milrinone : | I. V. administration. | | Indications : | Short term management of CCF in patient unresponsive to digitalis diuretics or vasodilators | | Contraindications : | Hypersensitivity | | Adverse Effects : | Ventricular arrhythmias, hypokalemia, tremors. | | Dosage : | Initially start with 0.5 mg/kg. Followed by intravenous infusion at a rate of 375-750 nanograms/kg/min. | | Purity : | Not less than 99%. |
|
 | |  |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
